Argen X SE ADR (ARGX) is overvalued and Royalty Pharma plc (RPRX) is overvalued.
Both trade above our estimate of their intrinsic value. ARGX is the closer of the two: -27%, against -49% for RPRX.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 8.0% (average of 3 methods) values the shares at $758.94; the price of $963.79 is 27% above that value, and 81% of that value comes from beyond year five.
Leak Score 59/100 on 3 of 12 signals
Discounting its cash flows at 7.7% (average of 3 methods) values the shares at $39.27; the price of $58.52 is 49% above that value, and 80% of that value comes from beyond year five.
Leak Score 34/100 on 7 of 12 signals
| Metric | ARGX | RPRX |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Price | $963.79 | $58.52 |
| Intrinsic value | $758.94 | $39.27 |
| Margin of safety | -27% | -49% |
| Leak Score | 59/100 (3/12) | 34/100 (7/12) |
| Market cap | $60.3B | $33.7B |
| Revenue growth, 5 years | 151.4% | 2.3% |
| Operating margin | 28.8% | 62.3% |
| Net margin | 32.8% | 32.1% |
| Return on equity | 23.6% | 12.4% |
| Debt to equity | 0.01 | 1.31 |
| P/E | 36.7x | 31.1x |
| Forward P/E | 25.1x | 10.2x |
| P/B | 7.1x | 3.8x |
| Dividend yield | — | 1.8% |